France Approves Gene Therapy Clinical Trial to Treat Hearing Loss in Children
The clinical trial will test a gene therapy drug to treat children with a form of hereditary deafness caused by mutations in the OTOF gene.
The clinical trial will test a gene therapy drug to treat children with a form of hereditary deafness caused by mutations in the OTOF gene.
Hearing loss has been linked to mutations in at least 100 different genes, but up to 16% of genetic hearing loss can be traced to just one gene, STRC, the second most common genetic cause. A first-of-its-kind gene therapy technique developed at Boston Children’s Hospital successfully replaced the mutated protein, stereocilin, in the inner ear and reversed severe hearing loss in mice — sometimes to normal levels of hearing.
A new study from Tel Aviv University (TAU) presents an innovative treatment for deafness, based on the delivery of genetic material into the cells of the inner ear. The genetic material “replaces” the genetic defect and enables the cells to continue functioning normally.
The aim of this project is to develop a specific gene therapy program aimed at correcting an inherited monogenic form of deafness caused by a mutation in the gene encoding for the Otoferlin protein (DNBF9).
Read MoreThe aim of this project is to develop a specific gene therapy program aimed at correcting an inherited monogenic form of deafness caused by a mutation in the gene encoding for the Otoferlin protein (DNBF9).
Read MoreSensorion and Institut Pasteur have leveraged the last six months to reach a partnership framework agreement. This agreement provides for, after completion of a research program, an exclusive option to obtain licenses.
Read MoreThe book describes major advances in our understanding of the pathogenic processes underlying various forms of hearing loss and the emergence of treatments for deafness.
Read MoreResearchers have managed to restore hearing in an adult mouse model of DFNB9 deafness, a hearing disorder that represents one of the most frequent cases of congenital genetic deafness
Read MoreSensorion announced a letter of intent with Pasteur Institute in Paris to exclusively negotiate a framework agreement to obtain the exclusive licenses to develop and commercialize gene therapy product candidates for restoration, treatment, and prevention of hearing loss disorders. They will collaborate on several lead programs to correct monogenic forms of hereditary hearing loss including, among others, the Usher syndrome type 1 and otoferlin deficiency, according to the announcement.
Read MoreThe investigation shows that the beneficial effects on cognition can be blocked by the hostile inflammatory environment present in the brains of patients with Alzheimer’s disease and that physical exercise can “clean up” the environment, allowing new nerve cells to survive, thrive, and improve cognition in the Alzheimer’s mice.
Read MoreAkouos is developing targeted adeno-associated viral vector (AAV)-based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and/or nerve fibers of the inner ear.
Read MoreAnc-AAVs are in silico-designed adeno-associated viral vectors (AAVs), first developed in the laboratory of Dr Luk H. Vandenberghe, assistant professor of ophthalmology at Harvard Medical School, and director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear.
Read MoreThe findings were published June 29 in “Nature Communications.“ The study is reportedly the first to illuminate in detail how a particular protein, which is known as CIB2, allows hearing to work.
Read MoreIn a first-of-its-kind study published in the March 1, 2017 edition of Molecular Therapy, researchers from the National Institute on Deafness and Other Communication Disorders (NIDCD) and Johns Hopkins University School of Medicine showed that gene therapy was able to restore balance and hearing in genetically modified mice that mimic Usher syndrome.
Read MoreTwo new papers published in Nature Biotechnology on February 6 detail research by scientists at Boston Children’s Hospital—a pediatric teaching hospital affiliated with Harvard Medical School—on an improved gene therapy that helps restore hearing to genetically deaf mice.
Read MoreUsing a novel form of gene therapy, scientists from Harvard Medical School and the Massachusetts General Hospital have managed to restore partial hearing and balance in mice born with a genetic condition that affects both. The new model reportedly overcomes a long-standing barrier to accessing hair cells which have been notoriously difficult to treat with previous gene-delivery techniques.
Read MoreScientists in Boston and Switzerland believe that their mice study of the TMC1 gene will lead to a gene therapy protocol for humans in roughly 5-10 years.
Read MoreScientists at Harvard University develop a system of genome-editing protein delivery that could treat or help cure many genetic diseases, including one linked to deafness.
Read More